Welcome to the e-CCO Library!

P443: Trough concentration response in infliximab and adalimumab treated children with IBD following treatment adjustment: A pharmacokinetic model.
Year: 2022
Source: ECCO'22
Authors: Levi, R.(1);Matar, M.(1);Zvoluni, M.(1);Shamir, R.(1);Assa, A.(1);
Created: Friday, 11 February 2022, 3:52 PM
P444 The impact of azathioprine on inflammatory bowel disease patients’ overall health-related quality of life: a single-centre retrospective cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. ALRUTHIA1, W. Alsharif1, G. Almuaythir1, H. Alrasheed1, O. Alharbi2, N. Azzam2, M. Almadi2, M. Saeed2, B. HajkhderMullaissa2, A. Aljebreen2

Created: Thursday, 30 January 2020, 10:12 AM
P444: A systematic literature review (SLR) of real-world studies of advanced therapies in moderate-to-severe ulcerative colitis (UC): study, patient and clinical characteristics, and outcomes assessed
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Irving, P.M.(1);Hur, P.(2)*;Gautam, R.(3);Guo, X.(4);Vermeire, S.(5);
Created: Friday, 14 July 2023, 11:05 AM
P444: COVID-19 risk factors, infection course and vaccination among patients with inflammatory bowel disease based on a Hungarian cohort
Year: 2022
Source: ECCO'22
Authors: Farkas, K.(1);Matuz, M.(2);Kata, D.(3);Földesi, I.(3);Resál, T.(1);Bacsur, P.(1);Szántó, K.(1);Kolarovszki-Erdei, D.(1);Rutka, M.(1);Fábián, A.(1);Bor, R.(1);Szepes, Z.(1);Sarlós, P.(4);Miheller, P.(5);Zacháry, A.(6);Molnár, T.(1);
Created: Friday, 11 February 2022, 3:52 PM
P444: Does one size truly fit all? Co-prescription of allopurinol and thiopurine therapy results in variation of TGNs outside the therapeutic range in more than half of patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Johnston E.*1, Warner B.1, Fong S.1, Arenas-Hernandez M.2, Marinaki A.2, Anderson S.1, Sanderson J.1, Irving P.1

Created: Wednesday, 20 February 2019, 10:36 AM
P444: Fecal calprotectin response to anti-tumor necrosis factor alpha induction and maintenance in Pediatric Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Matar, M.(1);Levi, R.(2);Zvuloni, M.(3);Shamir, R.(1,3);Assa, A.(1,4);
Created: Wednesday, 2 June 2021, 4:12 PM
P444: Post-induction Infliximab trough levels in severe and moderate paediatric ulcerative colitis: preliminary data of a retrospective, population cohort-based study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Martinelli*1,2, H. Moore2, N. Devas2, A. Galgano2, R. N. Baldassano2

Created: Friday, 22 February 2019, 9:41 AM
P445 Efficacy and safety of induction therapy with calcineurin inhibitors followed by maintenance therapy with vedolizumab in severe ulcerative colitis: a large patient cohort with long-term follow-up
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. OLLECH1, S. Dwadasi1, I. Normatov1, A. Israel1, V. Rai1, P. Sossenheimer1, B. Christensen2, S. Dalal1, J. Pekow1, A. Sakuraba1, R. Cohen1, D. Rubin1

Created: Thursday, 30 January 2020, 10:12 AM
P445: Does The Sequence Matter ? Comparative effectiveness of a second line biologic in patients with Ulcerative Colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
Year: 2021
Source: ECCO'21 Virtual
Authors: Miller, C.(1);Kwok, H.(1);Parisi, I.(1);Harrow, P.(1);McCartney, S.(1);Vega, R.(1);Rahman, F.(1);Seward, E.(1);Mehta, S.(1);Lim, S.(2);Sharma, E.(2);Samaan, M.(2);Bancil, A.(3);Kok, K.(3);Shalabi, A.(4);Johnston, E.(4);Katarey, D.(5);Taherzadeh, N.(5);Murray, C.(5);Sharip, M.(6);Carter, M.(6);Radhakrishnan, S.(7);Peake, S.(7);Khakoo, I.(8);Wahed, M.(8);Povlsen, S.(9);Patel, M.(9);Dubois, P.(9);Finkel, J.(10);Onnie, C.(10);Bloom, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P445: Early outcomes for adolescent inflammatory bowel disease patients treated in a transition clinic
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

I. Avni-Biron1, G. Fraser*1, Y. Rosenbach2, R. Shamir2, A. Assa2, L. Lichtenstein1, O. Ben-Bassat1

Created: Friday, 22 February 2019, 9:49 AM
P445: Is objective disease monitoring strategy tailored to the presence of clinical symptoms, a prospective cohort study from a tertiary IBD center from Hungary
Year: 2022
Source: ECCO'22
Authors: Lontai, L.(1);Gonczi, L.(1);Komlodi, N.(1);Balogh, F.(1);Barkai, L.(1);Ilias, A.(1);LakatosPhD, P.L.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P445: Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn's Disease and Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Peyrin-Biroulet, L.(1);Bossuyt, P.(2);Bettenworth, D.(3);Loftus Jr., E.V.(4);Anjie, S.(5);D'Haens, G.(5);Saruta, M.(6);Arkkila, P.(7);Kim, D.H.(8);Choi, D.(8);Reinisch, W.(9)*;
Created: Friday, 14 July 2023, 11:05 AM
P445: Patients with active perianal fistulas have a reduced physical health compared with Crohn’s patients without perianal fistulas
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. van der Voorn1,2*, M. Barnhoorn1, S. van Erp1, P. Maljaars3, M. Rodriquez Girondo4, A. Kaptein3, A. van der Meulen - de Jong1

Created: Thursday, 21 February 2019, 9:14 AM
P445: Perioperative use of vedolizumab seems not associated with short-term postoperative infectious complications in patients with Crohn's disease undergoing right hemicolectomy with ileocolonic anastomosis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Schils N.*1, De Buck van Overstraeten A.2, Vermeire S.1, Van Assche G.1, Wolthuis A.2, D'Hoore A.2, Ferrante M.1

Created: Wednesday, 20 February 2019, 10:36 AM
P445: Prevalence rates of biosimilar discontinuation and switchback to originator biologics following non-medical switching: a meta-analysis of real-world studies
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Yifei*1, M. Skup2, M. Yang3, C. Qi3, T. Doctor3

Created: Friday, 22 February 2019, 9:41 AM
P446 Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a TUSCANY study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Hassan-Zahraee1, Z. Ye1, L. Xi1, M.L. Baniecki1, X. Li1, W. Farin2, L. Tibaldi3, J.R. Allegretti4, J. Romatowski5, E.J. Scherl6, M. Klopocka7, C. Hyde1, S. Danese8, R. Longman6, K.E. Hung1

Created: Thursday, 30 January 2020, 10:12 AM
P446: Characterization of ulcerative colitis patients in the Golimumab PURSUIT-Maintenance study: post-hoc analyses of patients who maintained and did not maintain clinical response through week 54
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.J.1, Rutgeerts P.2, Zhang H.3, Adedokun O.J.3, Xu S.3, Shraim R.3, Marano C.*3

Created: Wednesday, 20 February 2019, 10:36 AM
P446: Dose escalation with originator infliximab is more common than standard dosing in paediatric IBD: the DEVELOP experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Escher*1, M. Dubinsky2, J. Izanec3, C. Busse3, Y. Wang4, A. Griffiths5

Created: Friday, 22 February 2019, 9:41 AM
P446: Effects of CYP3A5 genotype on efficacy and safety of tacrolimus in refractory ulcerative colitis: experience from a tertiary referral centre
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. Saito*, T. Kobayashi, M. Nakano, T. Toyonaga, S. Kuronuma, O. Takeuchi, H. Serizawa, N. Watanabe, T. Hibi

Created: Friday, 22 February 2019, 9:49 AM